DC-S239

Cat. No.:	HY-121093
CAS No.:	303141-21-1
Molecular Formula:	$C_{15}H_{15}N_3O_5S$
Molecular Weight:	349.36
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (357.80 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.8624 mL	14.3119 mL	28.6238 mL
	5 mM	0.5725 mL	2.8624 mL	5.7248 mL
	10 mM	0.2862 mL	1.4312 mL	2.8624 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC_{50} value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity[1].

IC_{50} & Target

IC50: 4.59 μM (SET7)[1]

In Vitro

DC-S239 inhibits DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a by less than 45%, while it inhibits SET7 by 90% at concentrations of 100 μM[1].

DC-S239 (0-100 μM, 120 h) can inhibit the proliferation of MCF7, HL60 and MV4-11 cells in a dose-dependent manner but no significant effect on the activity of HCT116 and DHL4 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	MCF7, HL60, DHL4, MV4-11 and HCT116 cell lines
Concentration:	0-100 μM

Incubation Time:	120 h
Result:	Inhibited MCF7 and HL60 with the IC_{50} values of 10.93 μM and 16.43 μM, respectively.

REFERENCES

[1]. Fanwang Meng, et al. Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. J Med Chem. 2015 Oct 22;58(20):8166-81.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA